Fengjiao Yuan

716 total citations
32 papers, 560 citations indexed

About

Fengjiao Yuan is a scholar working on Molecular Biology, Immunology and Biomaterials. According to data from OpenAlex, Fengjiao Yuan has authored 32 papers receiving a total of 560 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 14 papers in Immunology and 4 papers in Biomaterials. Recurrent topics in Fengjiao Yuan's work include Immunotherapy and Immune Responses (8 papers), RNA Interference and Gene Delivery (6 papers) and Nanoparticle-Based Drug Delivery (4 papers). Fengjiao Yuan is often cited by papers focused on Immunotherapy and Immune Responses (8 papers), RNA Interference and Gene Delivery (6 papers) and Nanoparticle-Based Drug Delivery (4 papers). Fengjiao Yuan collaborates with scholars based in China, Netherlands and Ukraine. Fengjiao Yuan's co-authors include Weiyun Zhang, Ping Dong, Bailing Zhou, Yaomei Tian, Guopu Chen, Xiao Fu, Hengfei Shi, Dan Song, Heng Xu and Yang Shu and has published in prestigious journals such as PLoS ONE, Scientific Reports and Journal of Controlled Release.

In The Last Decade

Fengjiao Yuan

27 papers receiving 556 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fengjiao Yuan China 14 232 182 97 87 64 32 560
Julio Lara‐Riegos Mexico 9 415 1.8× 127 0.7× 199 2.1× 76 0.9× 51 0.8× 29 952
Julio César Torres‐Romero Mexico 12 447 1.9× 141 0.8× 190 2.0× 75 0.9× 51 0.8× 42 1.0k
Pinelopi Samara Greece 13 251 1.1× 211 1.2× 166 1.7× 50 0.6× 41 0.6× 34 666
Priscilla Aparecida Tártari Pereira Brazil 13 216 0.9× 209 1.1× 63 0.6× 27 0.3× 76 1.2× 27 703
Mohd M. Khan United States 12 322 1.4× 197 1.1× 92 0.9× 47 0.5× 43 0.7× 23 650
Pablo Zapata‐Benavides Mexico 17 413 1.8× 186 1.0× 141 1.5× 107 1.2× 86 1.3× 47 934
Yanni Ma China 18 339 1.5× 79 0.4× 112 1.2× 47 0.5× 50 0.8× 50 761
Edgar Mendoza-Gamboa Mexico 15 196 0.8× 174 1.0× 85 0.9× 86 1.0× 38 0.6× 27 709
Lan Ma China 16 331 1.4× 115 0.6× 105 1.1× 110 1.3× 75 1.2× 37 887
Alireza Farasat Iran 14 351 1.5× 116 0.6× 59 0.6× 40 0.5× 40 0.6× 43 584

Countries citing papers authored by Fengjiao Yuan

Since Specialization
Citations

This map shows the geographic impact of Fengjiao Yuan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengjiao Yuan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengjiao Yuan more than expected).

Fields of papers citing papers by Fengjiao Yuan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fengjiao Yuan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengjiao Yuan. The network helps show where Fengjiao Yuan may publish in the future.

Co-authorship network of co-authors of Fengjiao Yuan

This figure shows the co-authorship network connecting the top 25 collaborators of Fengjiao Yuan. A scholar is included among the top collaborators of Fengjiao Yuan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fengjiao Yuan. Fengjiao Yuan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Feifei, Dianlong Jia, Jun Li, et al.. (2025). Co-delivery of TRAIL and bortezomib via liposomes demonstrates enhanced antitumor efficacy in vivo. Journal of Drug Delivery Science and Technology. 105. 106602–106602.
2.
Yan, Lili, Lili Yi, Conghui Tian, et al.. (2025). TMEM176B inhibits ovarian cancer progression by regulating EMT via the Wnt/β-catenin signaling pathway. Journal of Translational Medicine. 23(1). 350–350.
3.
Wang, Zhiyan, et al.. (2025). Skin microbiome and skin aging: emerging strategies for manipulation. Microbiological Research. 300. 128285–128285.
4.
Wang, Feifei, Yuxue Liu, Zi Chen, et al.. (2024). Improving Targeted Delivery and Antitumor Efficacy of TRAIL through Fusion with a B7H3-Antagonistic Affibody. Molecular Pharmaceutics. 22(1). 284–294. 1 indexed citations
5.
Chang, Rui, Rongrong Fu, Jibing Zhang, et al.. (2023). Codelivery of TRAIL and Mitomycin C via Liposomes Shows Improved Antitumor Effect on TRAIL-Resistant Tumors. Molecular Pharmaceutics. 20(6). 2864–2875. 6 indexed citations
6.
Jia, Dianlong, Yue Lu, Feifei Wang, et al.. (2023). Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy. Journal of Controlled Release. 360. 858–871. 13 indexed citations
7.
Yuan, Fengjiao, Weihua Zhang, Hui Guo, et al.. (2023). CXCL16 exacerbates Pseudomonas aeruginosa keratitis by promoting neutrophil activation. International Immunopharmacology. 127. 111375–111375. 2 indexed citations
8.
Yuan, Fengjiao, Jianmei Wei, Yan Cheng, et al.. (2023). SLAMF7 Promotes Foam Cell Formation of Macrophage by Suppressing NR4A1 Expression During Carotid Atherosclerosis. Inflammation. 47(2). 530–542. 7 indexed citations
9.
Liu, Huimin, Dianlong Jia, Fengjiao Yuan, et al.. (2022). Her3-specific affibody mediated tumor targeting delivery of ICG enhanced the photothermal therapy against Her3-positive tumors. International Journal of Pharmaceutics. 617. 121609–121609. 15 indexed citations
10.
Jia, Dianlong, Feifei Wang, Yujiao Yang, et al.. (2021). Coupling EGFR-Antagonistic Affibody Enhanced Therapeutic Effects of Cisplatin Liposomes in EGFR-expressing Tumor Models. Journal of Pharmaceutical Sciences. 111(2). 450–457. 8 indexed citations
11.
Wang, Haijun, Dianlong Jia, Dandan Yuan, et al.. (2021). Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy. Journal of Nanobiotechnology. 19(1). 138–138. 34 indexed citations
12.
Jia, Dianlong, Yujiao Yang, Fengjiao Yuan, et al.. (2020). Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models. International Journal of Pharmaceutics. 586. 119541–119541. 19 indexed citations
13.
Fan, Yingzi, Yandong Mu, Lian Lu, et al.. (2019). Hydrogen peroxide-inactivated bacteria induces potent humoral and cellular immune responses and releases nucleic acids. International Immunopharmacology. 69. 389–397. 21 indexed citations
14.
Zhang, Rui, Fengjiao Yuan, Yang Shu, et al.. (2019). Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models. Cancer Immunology Immunotherapy. 69(1). 135–145. 57 indexed citations
15.
16.
Zhou, Bailing, Xuyang Xia, Peiqi Wang, et al.. (2018). Induction and Amelioration of Methotrexate-Induced Gastrointestinal Toxicity are Related to Immune Response and Gut Microbiota. EBioMedicine. 33. 122–133. 105 indexed citations
17.
Tian, Yaomei, Meng Li, Chaoheng Yu, et al.. (2017). The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo. Oncotarget. 8(28). 45951–45964. 17 indexed citations
18.
Yu, Chaoheng, Zichao Luo, Meng Li, et al.. (2015). Synthetic innate defense regulator peptide combination using CpG ODN as a novel adjuvant induces long-lasting and balanced immune responses. Molecular Medicine Reports. 13(1). 915–924. 6 indexed citations
19.
Song, Dan, et al.. (2012). Regulation of the exopolysaccharide from an anamorph of Cordyceps sinensis on dendritic cell sarcoma (DCS) cell line. European Journal of Nutrition. 52(2). 687–694. 23 indexed citations
20.
Chen, Weixia, et al.. (2012). Modulatory effects of the acid polysaccharide fraction from one of anamorph of Cordyceps sinensis on Ana-1 cells. Journal of Ethnopharmacology. 142(3). 739–745. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julio Lara‐Riegos Breakdown of academic impact, for papers by Julio César Torres‐Romero Breakdown of academic impact, for papers by Pinelopi Samara Breakdown of academic impact, for papers by Priscilla Aparecida Tártari Pereira Breakdown of academic impact, for papers by Mohd M. Khan Breakdown of academic impact, for papers by Pablo Zapata‐Benavides Breakdown of academic impact, for papers by Yanni Ma Breakdown of academic impact, for papers by Edgar Mendoza-Gamboa Breakdown of academic impact, for papers by Lan Ma Breakdown of academic impact, for papers by Alireza Farasat
Rankless by CCL
2026